This inventor holds 2 USPTO granted patents. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991
Title: Yoji Sakurai: Innovator in Neuroprotective Compounds
Introduction
Yoji Sakurai is a prominent inventor based in Tokushima, Japan. He has made significant contributions to the field of neuroprotective compounds, holding a total of 2 patents. His work focuses on developing innovative solutions for nerve cell degeneration and related conditions.
Latest Patents
Sakurai's latest patents include a biphenyl derivative composition aimed at repairing nerve cell degeneration. This composition features a biphenyl derivative formula that serves as a protective agent for nerve cells. Additionally, he has developed novel hydrofluorene derivatives that exhibit excellent activities for improving anoxemic and hypoxic symptoms. These derivatives are not only useful as cerebral activators but also as preventive agents for arrhythmia and heart failure caused by oxygen shortages. Furthermore, they possess antioxidant properties, making them valuable in treating various disturbances caused by excessive active oxygen radicals.
Career Highlights
Yoji Sakurai is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate in the field of pharmaceuticals. His research has led to advancements that have the potential to improve the quality of life for individuals suffering from neurological conditions.
Collaborations
Sakurai has collaborated with notable colleagues, including Tatsuyoshi Tanaka and Hiroshi Okazaki. Their combined expertise has contributed to the success of their research endeavors.
Conclusion
Yoji Sakurai's work in developing neuroprotective compounds showcases his dedication to advancing medical science. His innovative patents reflect a commitment to improving health outcomes for those affected by nerve cell degeneration.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
